001     858397
005     20210129235938.0
024 7 _ |a 10.1016/j.antiviral.2018.10.019
|2 doi
024 7 _ |a 0166-3542
|2 ISSN
024 7 _ |a 1872-9096
|2 ISSN
024 7 _ |a pmid:30393012
|2 pmid
024 7 _ |a WOS:000451936000014
|2 WOS
024 7 _ |a altmetric:50880889
|2 altmetric
037 _ _ |a FZJ-2018-07283
082 _ _ |a 610
100 1 _ |a Coronado, Monika Aparecida
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Zika virus NS2B/NS3 proteinase: A new target for an old drug - Suramin a lead compound for NS2B/NS3 proteinase inhibition-
260 _ _ |a Amsterdam [u.a.]
|c 2018
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1546498016_29398
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Zika virus infection is the focus of much research due to the medical and social repercussions. Due the role of the viral NS2B/NS3 proteinase in maturation of the viral proteins, it had become an attractive antiviral target. Numerous investigations on viral epidemiology, structure and function analysis, vaccines, and therapeutic drugs have been conducted around the world. At present, no approved vaccine or even drugs have been reported. Thus, there is an urgent need to develop therapeutic agents to cure this epidemic disease. In the present study, we identified the polyanion suramin, an approved antiparasitic drug with antiviral properties, as a potential inhibitor of Zika virus complex NS2B/NS3 proteinase with IC50 of 47 μM. Using fluorescence spectroscopy results we could determine a kd value of 28 μM and had shown that the ligand does not affect the thermal stability of the protein. STD NMR spectroscopy experiments and molecular docking followed by molecular dynamics simulation identified the binding epitopes of the molecule and shows the mode of interaction, respectively. The computational analysis showed that suramin block the Ser135 residue and interact with the catalytically histidine residue.
536 _ _ |a 553 - Physical Basis of Diseases (POF3-553)
|0 G:(DE-HGF)POF3-553
|c POF3-553
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Eberle, Raphael Josef
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Bleffert, Nicole
|0 P:(DE-Juel1)131977
|b 2
|u fzj
700 1 _ |a Feuerstein, Sophie
|0 P:(DE-Juel1)162167
|b 3
|u fzj
700 1 _ |a Olivier, Danilo Silva
|0 0000-0003-1269-3783
|b 4
700 1 _ |a de Moraes, Fabio Rogerio
|0 0000-0002-0425-0352
|b 5
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 6
700 1 _ |a Arni, Raghuvir Krishnaswamy
|0 P:(DE-HGF)0
|b 7
|e Corresponding author
773 _ _ |a 10.1016/j.antiviral.2018.10.019
|g Vol. 160, p. 118 - 125
|0 PERI:(DE-600)1495861-2
|p 118 - 125
|t Antiviral research
|v 160
|y 2018
|x 0166-3542
856 4 _ |u https://juser.fz-juelich.de/record/858397/files/Zika%20virus%20NS2B%2CNS3%20proteinase%20A%20new%20target%20for%20an%20old%20drug%20-%20Suramin%20a%20lead%20compound%20for%20NS2B%2C%20NS3%20proteinase%20inhibition.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/858397/files/Zika%20virus%20NS2B%2CNS3%20proteinase%20A%20new%20target%20for%20an%20old%20drug%20-%20Suramin%20a%20lead%20compound%20for%20NS2B%2C%20NS3%20proteinase%20inhibition.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:858397
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)131977
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)162167
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)132029
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANTIVIR RES : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21